Aphidicolin CAS: 38966-21-1
MF: C20H34O4
MW: 338.48

Aphidicolin (CAS 38966-21-1)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 101ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Aphidicolin is rated 5.0 out of 5 by 2.
5
2
4
0
3
0
2
0
1
0
Nomi alternativi: Aphidicolin is also known as APC.
Applicazione: Aphidicolin is a novel tetracyclic diterpene antibiotic and also a DNA synthesis inhibitor in eukaryotes.
Numero CAS: 38966-21-1
Purezza: ≥98%
Peso molecolare: 338.48
Formula molecolare: C20H34O4
Solo per uso in Ricerca. Non previsto per Uso Diagnostico o Terapeutico.
* Vedere Certificato di Analisi per informazioni sul lotto specifico (incluso il contenuto d'acqua).

Aphidicolin is a diterpene fungal metabolite that blocks the cell cycle at early S-phase. In addition, Aphidicolin is a tetracyclic diterpene antibiotic with antiviral and antimitotic properties. Aphidicolin was first isolated from Cephelosporium aphidicola. Aphidicolin is a specific inhibitor of DNA polymerase α and δ in eukaryotic cells and in some viruses of animal origin. Aphidicolin is useful for cell synchronization. Aphidicolin blocks the cell cycle at early S phase. Aphidicolin prolongs the half life of DNA methyltransferase. Aphidicolin acts synergistically with vincristine and doxorubicin. In medicine, Aphidicolin may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells. Aphidicolin is also known as APC, ICI 69653, ICI-69653, ICI69653, and (3R,4R,4aR,6aS,8R,9R,11aS,11bS)-4,9-bis(hydroxymethyl)-4,11b-dimethyltetradecahydro-8,11a-methanocyclohepta[a]naphthalene-3,9-diol.


Referenze

1. Levenson, V. and Hamlin, J.L., Nucleic Acids Res. 21, 3997, (1993)
2. O′Dwyer, P.J. et al., Cancer Res. 54, 724, (1994)
3. Ikegami, S. et al., Nature 275, 458, (1978)
4. Schimke, R.T. et al. Philos. Trans. R. Soc. London B Biol. Sci. 345, 311, (1994)
5. Urbani, L. et al., Exp. Cell. Res. 219, 159, (1995)
6. Borner, M.M. et al., Cancer Res. 55, 2122, (1995)
7. Poluha, W. et al., Oncogene 10, 185, (1995)
8. Fan, X. and Price, C.M., Mol. Biol. Cell 8, 2145, (1997)
9. Suetake, I. et al., Cell Struct. Funct. 23, 137, (1998)
10. Michaelis, M. et al., Anticancer Drugs 11, 479, (2000)
11. Tedeschi, B. et al.; Mutat. Res. 546, 55, (2004)
12. S. Spadari, et al., TIBS 7, 29, (1982)

Utilizzo :
Aphidicolin is soluble in DMSO (50 mg/ml) and Methanol (10 mg/ml) purged in inert gas.
Stato fisico :
Solid
Solubilità :
Soluble in ethanol (1 mg/ml,stable at least a week at 4°C.), DMSO (10 mg/ml,stable at least six weeks at -20°C.), and methanol (10 mg/ml). Insoluble in water.
CONSERVAZIONE :
Store at -20° C
Punto di scioglimento :
227-233° C (lit.)
Punto di ebollizione :
457.85-557.8° C at 760 mmHg (Predicted)
Densità :
~1.2 g/cm3 (Predicted)
Indice di rifrazione :
n20D 1.59 (Predicted)
Attività ottica :
α27D +12, c = 1 in methanol
Solo per uso in Ricerca. Non previsto per Uso Diagnostico o Terapeutico.
WGK Germania :
3
RTECS :
PB9185000
PubChem CID :
Indice Merck :
14: 727
Numero MDL :
MFCD00083214
Registro Beilstein :
4689958

Download SDS (MSDS)

CERTIFICATO DI ANALISI

Adobe Acrobat Reader necessario per una visualizzazione affidabile,
stampa e commenta sui documenti PDF

Aphidicolin (CAS 38966-21-1)  Citazioni prodotti

Vedi quanti altri hanno usato Aphidicolin (CAS 38966-21-1). Clicca sulla voce per laccesso a PubMed .

Ciatazioni 1 a10 di 20 totali

PMID: # 33462217  Shaalan, AK.|Teshima, THN.|Tucker, AS.|Proctor, GB.| et al. 2021. Cell Death Discov. 7: 16.

PMID: # 30122350  Zhang, P. et al. 2018. Cell.

PMID: # 30006243  Luczak, MW.|Zhitkovich, A.| et al. 2018. Toxicol. Appl. Pharmacol. 355: 238-246.

PMID: # 30449723  Nojima, T.|Tellier, M.|Foxwell, J.|Ribeiro de Almeida, C.|Tan-Wong, SM.|Dhir, S.|Dujardin, G.|Dhir, A.|Murphy, S.|Proudfoot, NJ.| et al. 2018. Mol. Cell. 72: 970-984.e7.

PMID: # 28463988  Calton, CM.|Bronnimann, MP.|Manson, AR.|Li, S.|Chapman, JA.|Suarez-Berumen, M.|Williamson, TR.|Molugu, SK.|Bernal, RA.|Campos, SK.| et al. 2017. PLoS Pathog. 13: e1006200.

PMID: # 27534509  Wang, Y. et al. 2016. Glia. 64: 2154-2165.

PMID: # 26755699  Li, J. et al. 2016. Development (Cambridge, England). 143: 670-81.

PMID: # 27636097  Lewis, CW. et al. 2016. Cell Cycle. 15: 3131-3145.

PMID: # 12684394  Huron, DR. et al. 2003. Clin Cancer Res. 4: 1267-73.

PMID: # 11309295  Huang, S. et al. 2001. Cancer Res. 61: 3373-3381.

Ciatazioni 1 a10 di 20 totali
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 141ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 5ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

La Santa Cruz Biotechnology, Inc. è un leader mondiale nello sviluppo di prodotti per il mercato della ricerca biomedica. Chiamaci al numero gratuito 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. Tutti i diritti riservati. "Santa Cruz Biotechnology", ed il logo Santa Cruz Biotechnology, Inc."Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", il logo San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", ed "EZ Touch" sono marchi registrati dalla Santa Cruz Biotechnology, Inc.
Tutti i marchi sono proprietà dei rispettivi proprietari.